Open Access

Expression and localisation of c-kit and KITL in the adult human ovary

  • Astrud R Tuck1, 2,
  • Rebecca L Robker1,
  • Robert J Norman1,
  • Wayne D Tilley2 and
  • Theresa E Hickey1, 2Email author
Journal of Ovarian Research20158:31

https://doi.org/10.1186/s13048-015-0159-x

Received: 18 February 2015

Accepted: 14 May 2015

Published: 26 May 2015

Abstract

Background

The c-kit/kit ligand (KITL) signalling axis is an essential component of ovarian folliculogenesis in mammals, but little is known about expression and localisation of its key components in the ovaries of reproductive age women. This study aimed to characterise mRNA expression of c-kit and KITL isoforms and the localisation of c-kit and KITL proteins in adult human premenopausal ovaries.

Methods

This study utilised granulosa cells obtained from the preovulatory follicles of women undergoing assisted reproduction, pieces of ovarian tissue obtained from premenopausal women undergoing gynaecological surgeries and archival paraffin-embedded premenopausal ovarian tissues. Methodology included PCR for gene expression and Western blot or immunohistochemistry for protein expression.

Results

Both c-kit mRNA isoforms, known as GNNK+ and GNNK-, were detected in human ovarian cortex, while KITL protein isoforms (KITL1 and KITL2) were present in ovarian cortex and human granulosa cells. Immunohistochemistry showed expression of KITL and c-kit protein in multiple cell types within follicles throughout development, from primordial follicles to large antral follicles, in addition to atretic follicles. Oocytes of all follicle stages expressed c-kit protein exclusively. Interestingly, unlike animal models, expression of both proteins displayed a less cell-type specific distribution with immunostaining present in granulosa, theca and stromal cells, suggesting that autocrine signalling occurs within the human ovary.

Conclusion

The results of this study indicate that c-kit/KITL signalling also occurs in the human ovary, as established in various animal models, and may involve previously unknown autocrine signalling.

Keywords

Human Ovarian follicles c-kit KITL Immunohistochemistry Granulosa Theca PCOS

Background

KITL is a cytokine growth factor secreted by granulosa cells of ovarian follicles that exerts intra-follicular paracrine signals via stimulation of the c-kit receptor, which is expressed in theca cells and oocytes [13]. Transgenic mouse models have been utilised to demonstrate critical roles for the key ligand and receptor components of the c-kit/KITL signalling pathway during folliculogenesis ([48]; 2004). Expression and function of these key components have also been elucidated in other animal models including rat, rabbit, chicken, goat, pig and cow [1, 2, 911], and these have demonstrated several key roles that are essential for the maintenance of ovarian function and fertility. These roles include primordial follicle activation, promotion of primary to secondary follicle transition, preantral follicle growth, formation of the theca layer, thecal steroidogenesis and anti-apoptosis [3, 9].

Few studies have examined the expression and function of c-kit and KITL in human ovarian tissues. Evidence suggests that while c-kit/KITL signalling does not appear to be involved in human primordial follicle activation [12], it may have roles in follicle survival and thecal steroidogenesis similar to animal models. Currently, consensus is lacking over the cell type distribution of these two signalling proteins in human ovarian tissues [1214], which hampers understanding of their role in human ovarian function. Differences among studies may be largely due to the detection methodologies employed and the difficulty of obtaining human ovarian tissues that contain sufficient material to make conclusive observations. In one study, expression of KITL was found to be detected only in the oocytes of fetal and adult ovaries [14], a finding which is in stark contrast to animal studies where KITL protein is localised exclusively to granulosa cells. For c-kit expression, one study demonstrated the presence of c-kit protein on the membranes and cytoplasm of preantral granulosa cells of adult human ovaries [12], while another study reported the presence of c-kit protein only in the oocytes of preantral follicles [14]. These data that confine c-kit expression to the preantral follicle cohort are not consistent with the detection of soluble c-kit protein in the follicular fluid of antral follicles [13]. The latter finding suggests that the theca layer secretes soluble c-kit into the follicular fluid, although this remains to be confirmed. Inconsistencies in previous studies involving human ovarian tissues highlight the need for a more comprehensive study into the expression of the c-kit/KITL signalling pathway to reveal potential species differences.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with infertility and metabolic morbidities [15, 16]. Polycystic ovaries (PCO) are significantly enlarged, fibrotic, and contain an increased number of antral follicles in a state of developmental arrest. Although the specific roles of c-kit and KITL in the human ovary have not been established, based on their established roles in animal models perturbed KITL signalling could feasibly contribute to multiple phenotypic characteristics of PCO such as abnormal oocyte growth, increased follicle and stromal density, thecal hypertrophy, and increased thecal cell androgen biosynthesis [15, 1722]. To date, the c-kit/KITL signalling system has not been examined in relation to PCO or PCOS, in part because it is extremely difficult to obtain normal pre-menopausal ovarian tissues for comparison.

Numerous isoforms of KITL and c-kit have been described in the tissues of various animal species. In terms of KITL, most species, including humans, express two isoforms (KITL1 and KITL2) that arise via alternative mRNA splicing of the KITL gene. The chicken is uniquely reported to express six KITL isoforms in the ovary [23]. Two c-kit isoforms, known as GNNK+ and GNNK-, also arise by mRNA splicing and differ only by the presence or absence of four amino acids (GNNK) in the translated protein. These c-kit isoforms have been detected in the bovine ovary, but their expression in the reproductive tissues of other species remains unexplored. Animal studies have demonstrated the presence of KITL isoforms within the ovary, and mouse models have indicated the essential role of KITL2 for oocyte growth and survival [24]. To date, no study has ever comprehensively examined KITL or c-kit isoform expression in the human ovary.

To address current gaps in knowledge about the KITL/c-kit signalling pathway in the ovaries of reproductive age women, the specific aims for this study were to characterise the mRNA expression of c-kit and KITL isoforms and to localise c-kit and KITL protein in adult premenopausal human ovarian tissues, including ovarian tissues from women clinically diagnosed PCOS. This study demonstrates the presence of the KITL and c-kit protein throughout folliculogenesis in a less cell-type specific distribution than animal follicles. Furthermore, this study shows for the first time that KITL and c-kit isoforms are expressed in human ovarian tissue.

Materials and methods

Human ovarian tissue collection

Archival ovarian tissue

Formalin-fixed, paraffin-embedded ovarian tissues were obtained from hospital archives originally owned and operated by the Institute of Medical and Veterinary Science (IMVS; Adelaide, South Australia) under ethics approvals from the Royal Adelaide Hospital, the Central Northern Adelaide Health Service, and the University of Adelaide. Records corresponding to premenopausal women who had surgery for benign gynaecological conditions were collated and the associated tissue blocks were retrieved where possible. Fourteen tissues were collected and histologically assessed by a pathologist. Of these, six had histologically normal morphology and eight had morphology characteristic of polycystic ovaries (PCO), two of which had diagnoses of PCOS in the clinical notes. The mean age of non-PCOS patients was 35.5 years, while the mean age of PCOS patients was 37 years. Due to the limited information contained in the clinical notes of archival tissue, BMI was not available.

Within ovarian tissues, follicle classifications were performed as follows: a follicle was classified as primordial if it consisted of an oocyte surrounded by a single layer of flattened granulosa cells, and classified as primary if the oocyte was surrounded by a single layer of cuboidal granulosa cells. A secondary follicle had two or more layers of granulosa cells without an antrum, and an antral follicle had a large cavity, several layers of granulosa cells and a defined basal lamina and thecal layer. Large antral atretic follicles were classified by having an oocyte with an irregular membrane or a thinning layer of granulosa cells with pyknotic nuclei. Stages of atresia were assessed by the level of degradation of the granulosa cell layer and the appearance and definition of the basal lamina and theca layer. Germinal inclusion cysts were classified as fluid-filled cavities of various sizes situated in the cortex, surrounded by one or more layers of cuboidal or rectangular epithelial cells.

Fresh ovarian tissue

Fresh pieces of human ovarian cortex approximately 1 cm3 in size were obtained from consenting premenopausal (n = 3) women having oophorectomy as part of gynaecological surgery at the Royal Adelaide Hospital, South Australia, Australia. The study was approved by the ethics committees of the Royal Adelaide Hospital and the University of Adelaide. Tissue was immediately snap frozen upon collection and stored in liquid nitrogen.

Human granulosa cells

Following informed consent, mural granulosa cells (MGC) and cumulus granulosa cells (CGC) from pre-ovulatory follicles were collected from women (n = 4) who were receiving assisted reproduction at Repromed (Dulwich, South Australia). The study was approved by the ethics committees of the Women’s and Children’s Hospital, the University of Adelaide, and Repromed. All women underwent a standard hyperstimulation protocol with gonadotropin-releasing hormone (GnRH) down-regulation and subsequent gonadotrophin stimulation prior to oocyte retrieval. Cumulus-oocyte complexes were collected by transvaginal aspiration. MGCs were isolated by centrifugation of follicular fluid, mixed with PBS and layered onto onto a 50:50 v/v mixture of Percoll (Amersham Biosciences, Australia). After centrifugation to produce a density gradient, MGCs were removed and subjected to a second density gradient to remove any remaining blood contamination. Cells were washed in PBS and then pooled from all follicular aspirates representing one patient. Cumulus granulosa cells were removed from the oocyte by manually trimming (in vitro fertilisation) or hyaluronidase treatment (intracytoplasmic sperm injection). All cells were snap frozen and stored at −80 °C.

RNA isolation

Total RNA was extracted from cells using RNeasy Micro Kit (Qiagen, Hilden, Germany) with on-column DNase treatment (RNase-Free DNase Set, Qiagen) and RNA yield was assessed by spectrophotometer (ND-1000; NanoDrop Technologies Inc, Wilmington, DE, USA). Reverse transcription was performed on 100 ng of total RNA using the iScript First-Strand cDNA Synthesis Kit (Bio-Rad Laboratories, NSW, Australia).

Polymerase chain reaction

PCR to detect c-kit isoforms was performed using a primer pair designed to show both isoforms as previously described [25]: (forward: 5′-GGGGGATCCGATGTGGGCAAGACTTCT-3′; reverse 5′-CAGCAAAGGAGTGAACAG-3′). PCR was performed using a Pfu polymerase (Stratagene, La Jolla, CA, USA) and thermocycler conditions as follows: 94 °C for 7 min, then 25 cycles consisting of 94 °C for 1 min, 45 °C for 1 min and 72 °C for 12 min. PCR products were visualised on a 4 % agarose gel to detect products 93 and 81 bp in size (GNNK+ and GNNK–respectively). cDNA from the human leukaemic cell line, K562, was obtained from the Leukaemia Unit, Department of Molecular Pathology (SA Pathology, Adelaide, South Australia, Australia) and used as positive control for c-kit expression [26, 27].

Western blot

Human breast tissue was obtained from the Dame Roma Mitchell Cancer Research Laboratories (University of Adelaide, South Australia) for use as a positive control for c-kit immunostaining. Frozen ovarian cortex or frozen breast tissue, approximately 1 cm3, was ground to a fine powder using a mortar and pestle. Liquid nitrogen ensured that samples remained frozen at all times. Breast, ovarian cortex, MGC and CGC were lysed using RIPA buffer including protease inhibitor cocktail tablets, followed by centrifugation at 10,000 rpm for 10 min at 4 °C. Concentration of protein was determined using a Bradford protein assay at 595 nM. CCRF-HSB-2, a human leukaemic cell lysate, was commercially obtained for use as a positive control for c-kit (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as previously demonstrated [28] and used according to the supplier’s instructions.

Protein samples were prepared by adding 6x loading dye, denaturing at 100 °C for 5 min then centrifuging for 1 min. Proteins (20 μg) were electrophoresed on Criterion XT precast gels in 1x XT MOPS running buffer at 150 V for a total running time of 60–90 min. Precision Plus Protein Standards Dual Colour molecular weight marker was run alongside protein samples. Proteins were transferred to a Hybond-C nitrocellulose membrane under wet transfer conditions, using a Criterion Blotter according to the manufacturer’s instructions. Briefly, the transfer was set up in cold 1x transfer buffer with the gel and membrane stacked between Whatman filter paper, and transferred in cold 1x transfer buffer at 400 mA for 60–90 min. Protein transfer was checked by staining the membrane for 1 min in Ponceau stain, followed by brief rinsing in TBST. Membranes were blocked in TBST containing 3 % skim milk powder for 1 h, followed by incubation with either the c-kit primary antibody (1:1000, polyclonal rabbit anti-human CD117, DakoCytomation, Glostrup, Denmark) or the KITL primary antibody (1:1000; anti-stem cell factor, Millipore, Billerica, MA, USA) overnight at 4 °C. The appropriate HRP-conjugated secondary antibody (1:2000) was added for 30 min. Each primary and secondary antibody was diluted in TBST containing 1 % skim milk powder. Membranes were washed 3 times for 10 min in TBST following incubation with each antibody. All steps were performed with gently rotation at room temperature, except for overnight incubations which were performed at 4 °C. Bound antibody was visualised using SuperSignal West Dura Extended Duration Substrate, according to the manufacturer’s instructions, and exposed to Amersham Hyperfilm ECL. The film was developed in a dark room using standard developing and fixative reagents. Densitometry analysis was performed by measuring band intensity using the AlphaImager 2200 gel documentation system (Alpha Innotech, San Leandro, CA, USA).

Immunohistochemistry

A range of c-kit antibodies were tested and optimised using human ovarian tissue and human gastrointestinal stromal tumour (GIST) as a positive control (obtained from IMVS, Adelaide). From these, CD117 rabbit polyclonal antibody (DakoCytomation) was chosen as it was the antibody that provided a pattern of staining in GIST most similar to that used for diagnosis as shown in previous studies [29, 30], and had low background staining in ovarian test sections. This antibody has also been used in a previous study examining c-kit expression via immunohistochemistry in adult human ovaries [31]. No blocking peptide was available to confirm antibody specificity, but the presence of a single band on Western blot indicates the antibody is specific (Fig. 1b). Similarly, a range of KITL antibodies were tested and optimised using human breast carcinoma as a positive control (obtained from Dame Roma Cancer Research Laboratories, Adelaide). The antibody (Cell Signalling Technology, Inc., MA, USA) used in this study detects both isoforms as it was raised against a peptide sequence in the amino terminus of human KITL that is common to both isoforms, and this was confirmed in human breast carcinoma (data not shown). Antibody specificity in human ovarian tissue and breast carcinoma was confirmed by pre-absorption with the antigenic peptide (produced by Auspep, VIC, Australia, from the KITL sequence provided by Cell Signalling Technology), which resulted in a complete absence of staining in all tissue areas.
Fig. 1

c-kit and KITL isoforms are expressed in human ovary (a) c-kit isoforms, GNNK+ and GNNK−, were both present in ovarian cortex from three premenopausal women. Human leukaemia cell line K562 which expresses both isoforms was used as a positive control. (b) Western blot depicting a single 145 kDa band in human ovary and breast tissue lysates. CCRF-HSB-2 was used as a positive control and contains the 145kD band, representing glycosylated protein, as well as a smaller, 120kD, band representing non-glycosylated c-kit. (c) KITL protein isoform expression in the KGN human granulosa tumour cell line as a positive control, mural granulosa cells (MGC), cumulus cells (CC) and ovarian cortex containing some preantral follicles. Specific bands for KITL1 (36kD) and KITL2 (33kD) are present in all samples. An unknown 29kD band appears in the primary tissues but is absent in KGN cells. (d) Overnight incubation of the KITL antibody with its specific peptide demonstrates specificity

Immunohistochemistry was performed on tissue sections (3 μm) as previously described [32], except antigen retrieval in 10 mM citrate buffer (pH 6.5) was performed using a Decloaking Chamber (Biocare Medical, Concord, CA, USA) following the manufacturer’s protocol. Quenching of endogenous peroxidise activity (6 % H2O2 in methanol for 5 min at room temperature) was performed followed by blocking of non-specific antigens with 5 % goat serum in PBS for 1 h at room temperature. Tissues were stained with a 1:300 dilution of c-kit (CD117) (DakoCytomation, Glostrup, Denmark) or 1:100 dilution of KITL antibody (Cell Signalling Technology, Inc., MA, USA) overnight at 4 °C. A different KITL primary antibody to the one used for Western blot was utilised for immunohistochemistry, due to the Western blot antibody being unsuitable for use in immunohistochemistry. Visualisation of immunoreactivity was performed using a standard immunoperoxidase reaction. Biotinylated anti-rabbit antibody (1:400), streptavidin-HRP complex (1:500) and diaminobenzidine tetrahydrochloride was used to generate an insoluble brown deposit. Stained sections were scanned using the NanoZoomer image system (Hamamatsu, Japan) set at a magnification of 40X.

Results

c-kit mRNA and protein expression in human ovarian cortex

To examine the presence of GNNK c-kit mRNA isoforms, RT-PCR was performed on mRNA isolated from ovarian cortical tissue collected from pre-menopausal women (n = 3) between 40 and 50 years of age. Haematoxylin and eosin staining was performed in corresponding tissue sections, which revealed that several healthy preantral follicles were present within all the tissues (data not shown). Figure 1a shows the presence of two distinct PCR products in ovarian cortical tissue from three different patients as well as in K562 human leukaemia cells, which correspond to the GNNK+ (93 bp) and GNNK− (81 bp) isoforms. Although not quantitative, these results indicate that human ovarian cortical tissue expresses both mRNA isoforms of c-kit.

To examine the presence of c-kit protein, ovarian cortical tissue lysates were assessed by Western blot. Human leukaemic cell line lysate, CCRF-HSB-2, and human breast tissue lysate were used as positive controls since both have previously been shown to express c-kit [28, 33]. As expected, CCRF-HSB-2 cells possessed c-kit protein bands of 145 kDa and 120 kDa, thought to be glycosylated and unglycosylated forms of c-kit, respectively [34, 35]. Note that the GNNK+ and GNNK- isoforms cannot be distinguished via Western Blot due to the very small size difference between their corresponding proteins. Ovarian cortex and breast tissue lysates contained a single 145 kDa band (Fig. 1b), suggesting that unglycosylated forms of c-kit are not present. The KGN ovarian granulosa tumour cell line was added as a potential negative control for c-kit protein, as we were unable to detect mRNA for either c-kit isoform in this cell line (data not shown).

KITL protein isoform expression

To examine KITL protein isoform expression in samples representative of different stages of follicle development, Western blot was performed using lysates from: 1) KGN cells that have a phenotype similar to granulosa cells from preantral/ early antral follicles [36]; 2) human pre-menopausal ovarian cortex containing primordial and preantral follicles; 3) mural granulosa cells (MGC) aspirated from the pre-ovulatory follicles of a women receiving assisted reproduction and 4) cumulus granulosa cells (CGC) stripped from the cumulus-oocyte-complexes aspirated from the pre-ovulatory follicles of the same woman. KGN cells contained both KITL1 and KITL2 protein isoforms, detected as 36 kDa and 33 kDa bands as expected. Lysates derived from primary tissues also expressed both KITL isoforms to different degrees but an additional 29 kDa band was also consistently present (Fig. 1c). The Western blot shown is representative of three independent experiments. These qualitative findings were reproducible when analysing samples derived from other patients. Due to the nature of the samples, which represented either a whole tissue lysate or distinct enriched populations of cells, common loading control markers were not appropriate use and quantitative comparisons could not be made among the different samples. However, in general, levels of KITL2 (33 kDa) appeared proportionally higher than levels of KITL1 in KGN cells and ovarian cortical tissue, while levels of KITL1 appeared proportionally greater than KITL2 in MGC and CGC lysates. To further validate the specificity of each band, the KITL primary antibody was incubated overnight with a KITL peptide (Auspep, West Melbourne, VIC, Australia). The 29 kDa band was abolished along with the two expected KITL isoforms bands following peptide competition (Fig. 1d), suggesting that it is also an isoform of KITL, albeit one that is larger than the secreted form of KITL which is known to be approximately 18 kDa in size [9]. Interestingly, Ensembl Human (http://asia.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000049130;r=12:88492793-88534762;t=ENST00000378535) includes a transcript of a third KITL splice variant which encodes a protein of similar size to the 29 kDa band, suggesting that this protein may be a third isoform. Collectively, these observations suggest that KITL2 is the predominant isoform expressed during earlier stages of follicle development, while KITL1 is predominantly expressed in the later, preovulatory, stage.

c-kit and KITL expression and localisation throughout follicle development

To further localise c-kit and KITL protein expression, human ovarian sections were subjected to immunohistochemistry. The patterns of staining intensities observed in preantral and antral follicle types are summarised in Table 1. A human gastrointestinal stromal tumour (GIST) was used as a positive control for c-kit immunostaining (Additional file 1: Figure S1) as this antibody is routinely used for diagnosis of GIST [29, 30]. Human breast tissue was used as a positive control for KITL immunostaining (Additional file 2: Figure S2) and peptide competitions via incubation of the KITL primary antibody with its specific peptide abolished immunoreactivity in both breast and ovarian tissue (Additional file 2: Figure S2).
Table 1

Summary of the patterns of c-kit and KITL staining intensities observed in preantral and antral follicles

 

Primordial

Primary

 

Antral

 
 

OOC

GC

OOC

GC

OOC

GC

TH

c-kit

++/+++

─/+

++/+++

─/+

n/a

+

+

KITL

─/+

─/+

─/+

─/+

n/a

+/++

+/++

- negative; + weak; ++ moderate; +++ strong; n/a none available

OOC, oocyte; GC, granulosa cells; TH; theca layer

In primordial and primary follicles, c-kit immunostaining was present on the oolemma and also present in the ooplasm of the majority of oocytes (Fig. 2a, c). Some follicles also showed diffuse cytoplasmic staining in all granulosa cells surrounding the oocyte. Little to no staining was observed in the stromal cells surrounding follicles. KITL immunostaining was weak or absent in the ooplasm of primordial and primary follicles and in the cytoplasm of their associated GC (Fig. 2b, d). Sporadic, weak immunostaining was also observed in the stroma surrounding these follicles.
Fig. 2

c-kit and KITL are present in preantral follicles. Representative images of c-kit (a, c) and KITL (b, d) immunostaining in primordial (a, b) and primary (c, d) follicles. O: oocyte; G: granulosa cells. The open arrow indicates a primordial follicle

Antral follicles showed diffuse, weak cytoplasmic c-kit staining within granulosa cells and the thecal layer (Fig. 3a, c). Moderate cytoplasmic KITL staining was present within all granulosa cells and the thecal layer of antral follicles (Fig. 3b, d). Weak KITL immunostaining was present in adjacent stroma. There were no oocytes present in any of the antral follicles examined.
Fig. 3

c-kit and KITL are present in antral follicles. Representative images of c-kit (a, c) and KITL (b, d) immunostaining at low (a, b) and high (c, d) magnifications. A: antrum; G: granulosa cells; T: theca layer; S: stroma

Immunostaining was also examined in atretic follicles. A follicle in the early stages of atresia with an intact granulosa layer, basal lamina and theca layer showed diffuse cytoplasmic c-kit and KITL staining in the granulosa and theca cells (Fig. 4a, b). In a follicle with a degrading granulosa layer, c-kit and KITL staining remained present in the cytoplasm of apoptotic granulosa cells and theca cells (Fig. 4c, d). KITL and c-kit immunostaining was present in theca cells and the few remaining granulosa cells of a follicle with advanced atresia lacking distinction between the areas of remaining granulosa cells, basal lamina and theca layer (Fig. 4e, f).
Fig. 4

c-kit and KITL are expressed during various stages of atresia. (a, b) Intact granulosa layer, theca layer and basal lamina. (c, d) Disassociating granulosa cell layer with pyknotic nuclei. (e, f) Atretic follicle with little remaining of the granulosa layer and no distinction between the basal lamina and theca layer. A: antrum; G: granulosa cells; BL: basal lamina; T: theca layer; S: stroma

c-kit and KITL expression and localisation in ovarian follicles of women with PCOS

The cohort of ovarian tissues collected included two patients clinically diagnosed with PCOS. Interestingly, KITL staining was markedly more intense in granulosa cells, oocytes and surrounding stroma of follicles at all stages of development (Fig. 5) compared to follicles in non-PCOS ovaries (Figs. 2 and 3). While there were no secondary follicles present in non-PCOS ovaries for comparison, KITL staining was intense within the oocyte, granulosa cells and surrounding stroma cells of a secondary follicle present within one of the PCOS tissues (Fig. 5e, f). While the intensity of c-kit staining appeared no different in the two PCOS ovaries compared to non-PCOS, it was observed that oocytes in preantral follicles of PCOS patients more consistently exhibited strong oolemma staining. Moderate c-kit staining was present within the oolemma of the secondary follicle, and diffuse cytoplasmic staining was also present in granulosa cells and surrounding stroma cells (Fig. 5e, f). Granulosa cells of PCOS preantral follicles appeared to have mostly negative c-kit staining. C-kit immunostaining did not appear visually different in PCOS antral follicles compared to non-PCOS. Although this represents a small set of observations, the results are suggestive of an aberrant KITL/c-kit signalling axis in PCOS.
Fig. 5

c-kit and KITL in PCOS preantral and antral follicles. Representative images of primordial follicles (a, b), primary follicles (c, d), secondary follicles (e, f) and antral follicles (g, h). O: oocyte; G: granulosa cells

Discussion

This study demonstrates that the c-kit/KITL signalling pathway is expressed at multiple stages of follicular development in adult, reproductive age human ovaries. Moreover, this is the first study to document the presence of specific c-kit and KITL isoforms in human ovarian tissue. Their presence in preantral and antral follicle stages is indicative of their involvement in human folliculogenesis.

Unlike mouse ovaries, in which c-kit and KITL are expressed in distinct cellular compartments and signal exclusively in a paracrine manner, the expression pattern of c-kit and KITL in human ovaries displayed a less cell-type specific distribution. Human granulosa, theca and stromal cells all displayed at least some weak staining for both proteins, suggesting that autocrine signalling occurs in these cells types. The presence of c-kit protein in adult granulosa cells is supported by previous studies, which demonstrated the presence of c-kit mRNA and protein in pregranulosa cells and granulosa cells of primordial follicles in human fetal ovaries [12, 14, 37]. This finding suggests that the roles of KITL previously established in animal models may also be present in the human ovary, and furthermore, that these functions are perhaps regulated in a differential manner (e.g., autocrine versus paracrine). Given that KITL promotes preantral follicle growth and oocyte development [1, 3840], human preantral follicles that are positive for granulosa cell c-kit may possess a selective advantage over follicles that do not express the KITL receptor.

c-kit and KITL protein was also found to be co-expressed in the theca layer of all antral follicles. This suggests that the roles of KITL in formation and function of the theca layer, as shown in the bovine ovary [4143], may remain conserved in the human ovary. In contrast, a study examining c-kit immunostaining in human adult ovaries did not show any c-kit protein in the theca layer [12]. This is most likely due to the primary antibody used, ACK-2, which has been utilised primarily to inhibit c-kit in in vivo mechanistic studies rather than for immunohistochemistry. The antibody used in our study was carefully selected from a range of antibodies that were extensively tested, and has also been established in studies to be the most optimal and accurate antibody for use in diagnosis of GIST [29, 30]. No blocking peptide was available, but the presence of a single band on Western blot indicates the antibody is specific.

This study demonstrated that both KITL and c-kit are present in granulosa and thecal cells of antral follicles throughout atresia until cell layers have undergone total degradation. In sheep, KITL gene expression has been shown to be maintained in the granulosa cells of atretic follicles [44], while in mice, KITL expression disappears [5]. This is the first study to demonstrate the presence of c-kit expression in atretic follicles, and it is unclear whether the KITL/c-kit system plays an active role in dying follicles.

This study is the first to demonstrate KITL1 and KITL2 protein expression in human granulosa cell types. Interestingly, KGN cells, which are representative of preantral follicles, showed evidence of higher levels of KITL2 which may suggest a greater role for KITL during early follicle development. This isoform has been demonstrated to be crucial for fertility and normal folliculogenesis in mice [7, 45], in addition to mouse oocyte growth and survival in vitro [24]. The anchorage of KITL2 in the cell membrane is believed to be responsible for its prolonged receptor activation compared to KITL1, suggesting that KITL2 signalling may be more efficient and promotes sustained effects [46]. In our study, granulosa cells from preovulatory follicles showed higher levels of KITL1, which is believed to initiate shorter-term, transient effects due to faster receptor internalisation and degradation of the ligand/receptor complex [46]. Many established roles for KITL occur during earlier follicle development [9]. The presence of increased levels of KITL2 in preantral granulosa cells may suggest that KITL plays a greater or more prolonged role during early human folliculogenesis.

We also report for the first time that both GNNK+ and GNNK− mRNA isoforms of c-kit are present within the human premenopausal ovary, but it remains an important unanswered question which individual cell types specifically express each isoforms. In NIH3T3 fibroblast cells, GNNK− causes faster receptor phosphorylation and internalisation, and more extensive activation of the MAPK pathway than GNNK+ [25]. The presence of each isoform in the human ovary may suggest that regulation of KITL signalling occurs at the receptor level, and is determined by the particular c-kit isoform being expressed. This may have important implications in ovarian pathologies where perturbed c-kit/KITL signalling may play a role, such as PCOS which is mentioned further below. This observation, if confirmed in individual cell types, may provide some knowledge of the mechanisms of KITL signalling in the human ovary via activation of specific c-kit isoforms.

A limitation of our study that should be noted was the inability to quantify the levels of c-kit cDNA and KITL protein for comparison in each cell and tissue type. As these experiments were performed on whole tissue lysates and distinct, isolated cell types, a housekeeping gene or loading control marker could not be assumed to have consistent expression across each tissue type. Furthermore, we did not have the required numbers of participants to perform rigorous statistical analysis of expression levels. Thus, our study demonstrates only the presence of c-kit and KITL isoforms in ovarian tissues and cell types and is not able make quantitative conclusions on their expression levels.

Interestingly, this study observed markedly increased KITL immunostaining intensity in follicles at all stages of development within the two PCOS ovaries that were examined. Diffuse staining was also present within the oocytes of all preantral follicles, unlike the follicles of the morphologically normal ovaries examined in this study, suggesting altered expression of KITL in PCOS oocytes. It could be postulated that increased KITL levels in PCOS ovaries may underlie several of the abnormalities observed in PCOS, such as increased ovarian reserve [2, 4750] or enlarged oocytes [51], due to the diverse roles KITL has in animal models. Further study is required to confirm whether KITL protein is increased in PCOS using a larger sample size with ovarian tissues corresponding to women with more extensive clinical documentation for PCOS, including relative ovulation frequency.

In conclusion, this study has demonstrated the presence of KITL and c-kit in the adult human ovary throughout follicle development, in addition to showing the presence of each isoform. This suggests that the KITL/c-kit system is involved in human folliculogenesis, and further study is required to elucidate their roles and importance in human follicle development and fertility.

Abbreviations

KITL: 

Kit ligand

CGC: 

Cumulus granulosa cells

MGC: 

Mural granulosa cells

GIST: 

Gastrointestinal stromal tumours

PCOS: 

Polycystic ovary syndrome

Declarations

Acknowledgements

We thank Professor Tom Dodd and Dr Shalini Jindal for their morphological assessment of the archival ovarian tissues. We thank Mrs Joanna Gillis for technical assistance. We also thank the clinicians, nurses, embryology staff and consenting patients at Repromed for reviewing patient information, assistance in consenting patients and collecting tissues, or donating tissue for the purposes of this study. We acknowledge Professors Hajime Nawata and Toshihiko Yanase of Kyushu University and Professor Yoshihiro Nishi of Kurume University for creating and providing the KGN cell line. This work was supported by the National Health and Medical Research Council Project Grant (grant number 453628) to RJN, TEH and WDT; National Health and Medical Research Council Peter Doherty Fellowship to TEH; University of Adelaide Faculty of Health Sciences Divisional Scholarship to ART.

Funding

This work was supported by the National Health and Medical Research Council project grant (grant number 453628) to RJN, TEH and WDT; National Health and Medical Research Council Peter Doherty Fellowship to TEH; University of Adelaide Faculty of Health Sciences Divisional Scholarship to ART.

Authors’ Affiliations

(1)
Robinson Research Institute, School of Paediatrics and Reproductive Health
(2)
Dame Roma Mitchell Cancer Research Laboratories, School of Medicine; University of Adelaide

References

  1. Hutt KJ, McLaughlin EA, Holland MK. KIT/KIT ligand in mammalian oogenesis and folliculogenesis: roles in rabbit and murine ovarian follicle activation and oocyte growth. Biol Reprod. 2006;75:421–33.PubMedView ArticleGoogle Scholar
  2. Hutt KJ, McLaughlin EA, Holland MK. Kit ligand and c-Kit have diverse roles during mammalian oogenesis and folliculogenesis. Mol Hum Reprod. 2006;12:61–9.PubMedView ArticleGoogle Scholar
  3. Thomas FH, Vanderhyden BC. Oocyte-granulosa cell interactions during mouse follicular development: regulation of kit ligand expression and its role in oocyte growth. Reprod Biol Endocrinol. 2006;4:19.PubMed CentralPubMedView ArticleGoogle Scholar
  4. Brannan CI, Lyman SD, Williams DE, Eisenman J, Anderson DM, Cosman D, et al. Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc Natl Acad Sci U S A. 1991;88:4671–4.PubMed CentralPubMedView ArticleGoogle Scholar
  5. Manova K, Huang EJ, Angeles M, De Leon V, Sanchez S, Pronovost SM, et al. The expression pattern of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia. Dev Biol. 1993;157:85–99.PubMedView ArticleGoogle Scholar
  6. Bedell MA, Brannan CI, Evans EP, Copeland NG, Jenkins NA, Donovan PJ. DNA rearrangements located over 100 kb 5′ of the Steel (Sl)-coding region in Steel-panda and Steel-contrasted mice deregulate Sl expression and cause female sterility by disrupting ovarian follicle development. Genes Dev. 1995;9:455–70.PubMedView ArticleGoogle Scholar
  7. Tajima Y, Moore MA, Soares V, Ono M, Kissel H, Besmer P. Consequences of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. Proc Natl Acad Sci U S A. 1998;95:11903–8.PubMed CentralPubMedView ArticleGoogle Scholar
  8. Joyce IM, Pendola FL, Wigglesworth K, Eppig JJ. Oocyte regulation of kit ligand expression in mouse ovarian follicles. Dev Biol. 1999;214:342–53.PubMedView ArticleGoogle Scholar
  9. Driancourt MA, Reynaud K, Cortvrindt R, Smitz J. Roles of KIT and KIT LIGAND in ovarian function. Rev Reprod. 2000;5:143–52.PubMedView ArticleGoogle Scholar
  10. Brankin V, Hunter MG, Horan TL, Armstrong DG, Webb R. The expression patterns of mRNA-encoding stem cell factor, internal stem cell factor and c-kit in the prepubertal and adult porcine ovary. J Anat. 2004;205:393–403.PubMed CentralPubMedView ArticleGoogle Scholar
  11. Silva JR, van den Hurk R, van Tol HT, Roelen BA, Figueiredo JR. The Kit ligand/c-Kit receptor system in goat ovaries: gene expression and protein localization. Zygote. 2006;14:317–28.PubMedView ArticleGoogle Scholar
  12. Carlsson IB, Laitinen MP, Scott JE, Louhio H, Velentzis L, Tuuri T, et al. Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction. 2006;131:641–9.PubMedView ArticleGoogle Scholar
  13. Tanikawa M, Harada T, Mitsunari M, Onohara Y, Iwabe T, Terakawa N. Expression of c-kit messenger ribonucleic acid in human oocyte and presence of soluble c-kit in follicular fluid. J Clin Endocrinol Metab. 1998;83:1239–42.PubMedView ArticleGoogle Scholar
  14. Abir R, Fisch B, Jin S, Barnnet M, Kessler-Icekson G, Ao A. Expression of stem cell factor and its receptor in human fetal and adult ovaries. Fertil Steril. 2004;82 Suppl 3:1235–43.PubMedView ArticleGoogle Scholar
  15. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.Google Scholar
  16. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.PubMedView ArticleGoogle Scholar
  17. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called “hyperthecosis”. Obstet Gynecol Surv. 1982;37:59–77.PubMedView ArticleGoogle Scholar
  18. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994;79:1158–65.PubMedGoogle Scholar
  19. Nelson VL, Legro RS, Strauss 3rd JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13:946–57.PubMedView ArticleGoogle Scholar
  20. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362:1017–21.PubMedView ArticleGoogle Scholar
  21. Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Chang RJ, et al. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5321–7.PubMedView ArticleGoogle Scholar
  22. Stubbs SA, Stark J, Dilworth SM, Franks S, Hardy K. Abnormal preantral folliculogenesis in polycystic ovaries is associated with increased granulosa cell division. J Clin Endocrinol Metab. 2007;92:4418–26.PubMedView ArticleGoogle Scholar
  23. Wang Y, Li J, Ying Wang C, Yan Kwok AH, Leung FC. Epidermal growth factor (EGF) receptor ligands in the chicken ovary: I. Evidence for heparin-binding EGF-like growth factor (HB-EGF) as a potential oocyte-derived signal to control granulosa cell proliferation and HB-EGF and kit ligand expression. Endocrinology. 2007;148:3426–40.PubMedView ArticleGoogle Scholar
  24. Thomas FH, Ismail RS, Jiang JY, Vanderhyden BC. Kit ligand 2 promotes murine oocyte growth in vitro. Biol Reprod. 2008;78:167–75.PubMedView ArticleGoogle Scholar
  25. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts. Oncogene. 1999;18:5573–81.PubMedView ArticleGoogle Scholar
  26. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, et al. Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med. 1991;174:63–71.PubMedView ArticleGoogle Scholar
  27. Xie ZN, Liu DS, Cao WK, Deng ZK, Li YF. Influence of celecoxib combined with IFN-alpha on proliferation, apoptosis, cell cycle and CD117 expression of K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010;18:330–4.PubMedGoogle Scholar
  28. Li J, Quirt J, Do HQ, Lyte K, Fellows F, Goodyer CG, et al. Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas. Am J Physiol Endocrinol Metab. 2007;293:E475–83.PubMedView ArticleGoogle Scholar
  29. Wong NA, Melegh Z. Antigen retrieval and primary antibody type affect sensitivity but not specificity of CD117 immunohistochemistry. Histopathology. 2009;54:529–38.PubMedView ArticleGoogle Scholar
  30. Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57:259–70.PubMedView ArticleGoogle Scholar
  31. Liu Y, Wu C, Lyu Q, Yang D, Albertini DF, Keefe DL, et al. Germline stem cells and neo-oogenesis in the adult human ovary. Dev Biol. 2007;306:112–20.PubMedView ArticleGoogle Scholar
  32. Ricciardelli C, Choong CS, Buchanan G, Vivekanandan S, Neufing P, Stahl J, et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate. 2005;63:19–28.PubMedView ArticleGoogle Scholar
  33. Amin MM, El-Hawary AK, Farouk O. Relation of CD117 immunoreactivity and microvascular density in invasive breast carcinoma. Indian J Pathol Microbiol. 2012;55:456–60.PubMedView ArticleGoogle Scholar
  34. Reith AD, Ellis C, Lyman SD, Anderson DM, Williams DE, Bernstein A, et al. Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J. 1991;10:2451–9.PubMed CentralPubMedGoogle Scholar
  35. Koch D, Sakurai M, Hummitzsch K, Hermsdorf T, Erdmann S, Schwalbe S, et al. KIT variants in bovine ovarian cells and corpus luteum. Growth Factors. 2009;27:100–13.PubMedView ArticleGoogle Scholar
  36. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 2001;142:437–45.PubMedView ArticleGoogle Scholar
  37. Hoyer PE, Byskov AG, Mollgard K. Stem cell factor and c-Kit in human primordial germ cells and fetal ovaries. Mol Cell Endocrinol. 2005;234:1–10.PubMedView ArticleGoogle Scholar
  38. Klinger FG, De Felici M. In vitro development of growing oocytes from fetal mouse oocytes: stage-specific regulation by stem cell factor and granulosa cells. Dev Biol. 2002;244:85–95.PubMedView ArticleGoogle Scholar
  39. Muruvi W, Picton HM, Rodway RG, Joyce IM. In vitro growth of oocytes from primordial follicles isolated from frozen-thawed lamb ovaries. Theriogenology. 2005;64:1357–70.PubMedView ArticleGoogle Scholar
  40. John GB, Shidler MJ, Besmer P, Castrillon DH. Kit signaling via PI3K promotes ovarian follicle maturation but is dispensable for primordial follicle activation. Dev Biol. 2009;331:292–9.PubMed CentralPubMedView ArticleGoogle Scholar
  41. Parrott JA, Skinner MK. Direct actions of kit-ligand on theca cell growth and differentiation during follicle development. Endocrinology. 1997;138:3819–27.PubMedGoogle Scholar
  42. Parrott JA, Skinner MK. Thecal cell-granulosa cell interactions involve a positive feedback loop among keratinocyte growth factor, hepatocyte growth factor, and Kit ligand during ovarian follicular development. Endocrinology. 1998;139:2240–5.PubMedGoogle Scholar
  43. Parrott JA, Skinner MK. Kit ligand actions on ovarian stromal cells: effects on theca cell recruitment and steroid production. Mol Reprod Dev. 2000;55:55–64.PubMedView ArticleGoogle Scholar
  44. Tisdall DJ, Quirke LD, Smith P, McNatty KP. Expression of the ovine stem cell factor gene during folliculogenesis in late fetal and adult ovaries. J Mol Endocrinol. 1997;18:127–35.PubMedView ArticleGoogle Scholar
  45. Brannan CI, Bedell MA, Resnick JL, Eppig JJ, Handel MA, Williams DE, et al. Developmental abnormalities in Steel17H mice result from a splicing defect in the steel factor cytoplasmic tail. Genes Dev. 1992;6:1832–42.PubMedView ArticleGoogle Scholar
  46. Miyazawa K, Williams DA, Gotoh A, Nishimaki J, Broxmeyer HE, Toyama K. Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. Blood. 1995;85:641–9.PubMedGoogle Scholar
  47. Parrott JA, Skinner MK. Kit-ligand/stem cell factor induces primordial follicle development and initiates folliculogenesis. Endocrinology. 1999;140:4262–71.PubMedGoogle Scholar
  48. Reynaud K, Cortvrindt R, Smitz J, Driancourt MA. Effects of Kit Ligand and anti-Kit antibody on growth of cultured mouse preantral follicles. Mol Reprod Dev. 2000;56:483–94.PubMedView ArticleGoogle Scholar
  49. Jin X, Han CS, Yu FQ, Wei P, Hu ZY, Liu YX. Anti-apoptotic action of stem cell factor on oocytes in primordial follicles and its signal transduction. Mol Reprod Dev. 2005;70:82–90.PubMedView ArticleGoogle Scholar
  50. Jin X, Han CS, Zhang XS, Yuan JX, Hu ZY, Liu YX. Signal transduction of stem cell factor in promoting early follicle development. Mol Cell Endocrinol. 2005;229:3–10.PubMedView ArticleGoogle Scholar
  51. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008;14:367–78.PubMedView ArticleGoogle Scholar

Copyright

© Tuck et al. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement